12.04.23 -- Single-Use Bioreactors Gain Popularity Worldwide

New, intelligent freezing point depression technology has been developed and evaluated for its ability to aid biologics manufacturers in dealing with the expanding use of subcutaneous injections.

Primary packaging components require a thorough assessment to ensure safety and efficacy. Plan ahead and start your assessment early to mitigate your risks, delays, and out-of-pocket costs.

Learn about strategies to meet the quality and regulatory requirements of cell and gene therapies, as well as how to identify issues early on, avoid delays, and reduce quality and compliance risks.

Learn what some practical considerations are for implementing NAT-based methods, where concrete recommendations are necessary, and how guidelines can remain relevant for new medicinal products.

This webinar focuses on the role osmolality plays in developing formulations as new drug classes and compositions are being investigated.

Improve your rapid adventitious virus detection and significantly reduce the overall turnaround time for a bulk harvest testing package using a CHO animal origin free panel.

Several life cycle assessments have been conducted comparing the environmental impact of SUTs to conventional fixed systems, leading to results that could inform changes in bioprocess system use.

Increased investment in allogeneic therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

To find the plasmid manufacturer with the appropriate knowledge and experience to manufacture your plasmid with quality and efficiency, you’ll need to recognize the offerings of a seasoned supplier.

The promise of bispecific antibodies stems from their off-the-shelf nature and ability to bind to two or more different targets or epitopes, thereby performing multiple functions.

Learn more about an effective, biodegradable solution for the viral inactivation process that controls protein impurities and is compatible with downstream unit operations.

We address the additional compliance challenge in biopharma of the requirement of complex analytical instruments that are not traditionally used in highly regulated labs.

A panel of product development experts examine blind spots that can plague early development strategies, as well as important considerations when navigating the path toward an IND submission.

Accurately monitoring process parameters and bioreactor performance while leveraging process analytical technologies can lead to strong improvements in productivity, quality, and process stability.

Explore the results when two bsAbs produced in CHO cells were evaluated using both a Protein A resin specifically designed to bind to the Fc region and a conventional Protein A resin.